Determination of the survival rate in patients with congestive heart failure stratified by 123I-MIBG imaging: A meta-analysis from the studies performed in Japan

Annals of Nuclear Medicine

Volumn 25, Issue 2, 2011, Pages 101-107

  Kuwabara, Yoichi ^a   Tamaki, Nagara ^b   Nakata, Tomoaki ^c   Yamashina, Shohei ^d   Yamazaki, Junichi ^d  

^a CHIBA UNIVERSITY   (Japan)

^b HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d TOHO UNIVERSITY OMORI MEDICAL CENTER   (Japan)

Author keywords

123I MIBG imaging; Cardiac death; Heart failure; Meta analysis

Indexed keywords

METAIODOBENZYLGUANIDINE IODINE 123; RADIOISOTOPE; UNCLASSIFIED DRUG;

ARTICLE; CARDIAC IMAGING; CONGESTIVE HEART FAILURE; HEART DEATH; HUMAN; JAPAN; LIFE TABLE; MEDIASTINUM; META ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL RATE; SYSTEMATIC REVIEW;

3-IODOBENZYLGUANIDINE; HEART FAILURE; HUMANS; JAPAN; PROGNOSIS; SURVIVAL RATE; TIME FACTORS;

EID: 79954438987     PISSN: 09147187     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12149-010-0452-0     Document Type: Article

References (26)

1. Wieland DM, Rosenspire KC, Hutchins GD, Van Dort M, Rothley JM, Mislankar SG, et al. Neuronal mapping of the heart with 6-[18F]fluorometaraminol. J Med Chem. 1990;33:956-64.
2. Rosenspire KC, Haka MS, Van Dort ME, Jewett DM, Gildersleeve DL, Schwaiger M, et al. Synthesis and preliminary evaluation of carbon-11-meta- hydroxyephedrine: a false transmitter agent for heart neuronal imaging. J Nucl Med. 1990;31:1328-34. (Pubitemid 20245929)
3. Raffel DM, Corbett JR, del Rosario RB, Gildersleeve DL, Chiao PC, Schwaiger M, et al. Clinical evaluation of carbon-11-phenylephrine: MAO-sensitive marker of cardiac sympathetic neurons. J Nucl Med. 1996;37:1923-31. (Pubitemid 26428355)
4. Degrado TR, Zalutsky MR, Vaidyanathan G. Uptake mechanisms of meta-[123I]iodobenzylguanidine in isolated rat heart. Nucl Med Biol. 1995;22:1-12.
5. Nakajima K, Taki J, Tonami N, Hisada K. Decreased 123I-MIBG uptake and increased clearance in various cardiac diseases. Nucl Med Commun. 1994;15:317-23. (Pubitemid 24163899)
6. Bengel FM, Barthel P, Matsunari I, Schmidt G, Schwaiger M. Kinetics of 123I-MIBG after acute myocardial infarction and reperfusion therapy. J Nucl Med. 1999;40:904-10. (Pubitemid 29269208)
7. Yamada T, Shimonagata T, Fukunami M, Kumagai K, Ogita H, Hirata A, et al. Comparison of the prognostic value of cardiac iodine-123 metaiodobenzylguanidine imaging and heart rate variability in patients with chronic heart failure: a prospective study. J Am Coll Cardiol. 2003;41:231-8. (Pubitemid 36092191)
8. Patel AD, Iskandrian AE. MIBG imaging. J Nucl Cardiol. 2002;9:75-94. (Pubitemid 34196234)
9. Nakata T, Miyamoto K, Doi A, Sasao H, Wakabayashi T, Kobayashi H, et al. Cardiac death prediction and impaired cardiac sympathetic innervation assessed by MIBG in patients with failing and nonfailing hearts. J Nucl Cardiol. 1998;5:579-90. (Pubitemid 29015414)
10. Nakata T, Wakabayashi T, Kyuma M, Takahashi T, Hashimoto A, Ogata H. Prognostic implications of an initial loss of cardiac metaiodobenzylguanidine uptake and diabetes mellitus in patients with left ventricular dysfunction. J Card Fail. 2003;9:113-21. (Pubitemid 36444196)
11. Kyuma M, Nakata T, Hashimoto A, Nagao K, Sasao H, Takahashi T, et al. Incremental prognostic implications of brain natriuretic peptide, cardiac sympathetic nerve innervation, and noncardiac disorders in patients with heart failure. J Nucl Med. 2004;45:155-63. (Pubitemid 47628373)
12. Matsui T, Tsutamoto T, Maeda K, Kusukawa J, Kinoshita M. Prognostic value of repeated 123I-metaiodobenzylguanidine imaging in patients with dilated cardiomyopathy with congestive heart failure before and after optimized treatments-comparison with neurohumoral factors. Circ J. 2002;66:537-43. (Pubitemid 34733491)
13. Momose M, Kobayashi H, Iguchi N, Matsuda N, Sakomura Y, Kasanuki H, et al. Comparison of parameters of 123I-MIBG scintigraphy for predicting prognosis in patients with dilated cardiomyopathy. Nucl Med Commun. 1999;20:529-35. (Pubitemid 29509990)
14. Imamura Y, Fukuyama T, Mochizuki T, Miyagawa M, Watanabe K, Ehime MIBG Heart Failure Study Investigators. Prognostic value of iodine-123- metaiodobenzylguanidine imaging and cardiac natriuretic peptide levels in patients with left ventricular dysfunction resulting from cardiomyopathy. Jpn Circ J. 2001; 65:155-60.
15. Fujimoto S, Amano H, Inoue A, Ishida S, Yamashina S, Yamashina H, et al. Usefulness of 123I-metaiodobenzylguanidine myocardial scintigraphy in the prediction of cardiac events in patients with cardiomyopathy showing stabilization of symptoms or preserved cardiac function. Ann Nucl Med. 2004;18:591-8. (Pubitemid 39612243)
16. Merlet P, Benvenuti C, Moyse D, Pouillart F, Dubois-Randé JL, Duval AM, et al. Prognostic value of MIBG imaging in idiopathic dilated cardiomyopathy. J Nucl Med. 1999;40:917-23. (Pubitemid 29269210)
17. Agostini D, Verberne HJ, Burchert W, Knuuti J, Povinec P, Sambuceti G, et al. I-123-mIBG myocardial imaging for assessment of risk for a major cardiac event in heart failure patients: insights from a retrospective European multicenter study. Eur J Nucl Med Mol Imaging. 2008;35:535-46.
18. Verberne HJ, Brewster LM, Somsen GA, van Eck-Smit BL. Prognostic value of myocardial 123I-metaiodobenzylguanidine (MIBG) parameters in patients with heart failure: a systematic review. Eur Heart J. 2008;29:1147-59. (Pubitemid 351844881)
19. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med. 1998;17(24):2815-34. (Pubitemid 28562978)
20. Petitti DB. Meta-analysis, decision analysis, and cost-effective analysis. New York: Oxford University Press; 2000. p. 117-8.
21. Higgins JP, Thompson SG. Quantifying heterogeneity in a metaanalysis. Stat Med. 2002;15(21):1539-58.
22. Knickmeier M, Matheja P, Wichter T, Schäfers KP, Kies P, Breithardt G, et al. Clinical evaluation of no-carrier-added meta- [123I] iodobenzylguanidine for myocardial scintigraphy. Eur J Nucl Med. 2000;27:302-7. (Pubitemid 30167700)
23. Farahati J, Bier D, Scheubeck M, Lassmann M, Schelper LF, Grelle I, et al. Effect of specific activity on cardiac uptake of iodine-123-MIBG. J Nucl Med. 1997;38:447-51. (Pubitemid 27376901)
24. Verberne HJ, Habraken JB, van Eck-Smit BL, Agostini D, Jacobson AF. Variations in 123I-metaiodobenzylguanidine (MIBG) late heart mediastinal ratios in chronic heart failure: a need for standardisation and validation. Eur J Nucl Med Mol Imaging. 2008;35:547-53. (Pubitemid 351661673)
25. Nakajima K. Normal values for nuclear cardiology: Japanese databases for myocardial perfusion, fatty acid and sympathetic imaging and left ventricular function. Ann Nucl Med. 2010;24(3):125-35.
26. Yamashina S, et al. Role of MIBG myocardial scintigraphy in the assessment of heart failure: the need to establish evidence. Eur J Nucl Med Mol Imaging. 2004;31:1353.